The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Ruxolitinib for myelofibrosis: combinations and dosing strategy
Ruben Mesa, MD of the Mayo Clinic, Phoenix, AZ talks about ruxolitinib for myelofibrosis. In the long-term, ruxolitinib is favorable, with clear survival advantages. Individuals with extra anemia that develops with ruxolitinib probably do not have their survival limited in any way. Further, some combinations are promising; in particular, ruxolitinib with hypomethylation therapy (azacitidine or decitabine) in at least a subset of patients such those with more advanced disease. Additionally, Prof. Mesa suggests that the best dosing strategy is to use ruxolitinib first, then adding a hypomethylating agent as a second component as opposed to starting them concurrently. Furthermore, preliminary results of a study with ruxolitinib in combination with a PI3K delta inhibitor, TGR-1202 (NCT02493530), were favorable. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
